Trace amines are an endogenous group of amines structurally and metabolically related to classical monoamine neurotransmitters, such as dopamine, norepinephrine, and serotonin. Compared to the classical monoamines, they are present in trace concentrations. They are distributed heterogeneously throughout the mammalian brain and peripheral nervous tissues and exhibit high rates of metabolism. Although they can be synthesized within parent monoamine neurotransmitter systems, there is evidence that suggests that some of them may comprise their own independent neurotransmitter systems.[1]
Trace amines may play very significant roles in the coordination of biogenic monoamine-based synaptic physiology. At high concentrations, they have well-characterized presynaptic ‘‘amphetamine-like’’ effects on monoamine release, reuptake and biosynthesis; at lower concentrations, they possess postsynaptic modulatory effects that potentiate the activity of other neurotransmitters, particularly dopamine and serotonin.[1] A family of G protein coupled receptors known as TAARs (trace amine associated receptors) has been characterized to be responsive to trace amines[2] and structurally related psychoactive drugs, such as amphetamine, MDMA, LSD, and DMT.[3] Like dopamine, noradrenaline, and serotonin, the trace amines have been implicated in a vast array of human disorders of affect and cognition, such as depression[4] and schizophrenia.[5]
A thorough review of trace amines and trace amine receptors that discusses the historical evolution of this research particularly well is that of Grandy.[6]
List of trace amines
Metabolic pathway of phenylalanine
L-Phenylalanine
L-Tyrosine
L-Dopa
COMT
Phenethylaminergic trace amines and the catecholamines are derivatives of phenylalanine.
See also
References
- ↑ 1.0 1.1 Burchett SA, Hicks TP. The mysterious trace amines: protean neuromodulators of synaptic transmission in mammalian brain. Prog Neurobiol. 2006 Aug;79(5-6):223-46.
- ↑ Lindemann L, Ebeling M, Kratochwil NA, Bunzow JR, Grandy DK, Hoener MC. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics. 2005 Mar;85(3):372-85.
- ↑ Bunzow JR, Sonders MS, Arttamangkul S, Harrison LM, Zhang G, Quigley DI, Darland T, Suchland KL, Pasumamula S, Kennedy JL, Olson SB, Magenis RE, Amara SG, Grandy DK. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol. 2001 Dec;60(6):1181-8.
- ↑ Davis, B.A., Boulton, A.A., 1994. The trace amines and their acidic metabolites in depression—an overview. Prog. Neuropsychopharmacol. Biol. Psychiatry 18, 17–45.
- ↑ O’Reilly, R.L., Davis, B.A., 1994. Phenylethylamine and schizophrenia. Prog Neuropsychopharmacol. Biol. Psychiatry 18, 63–75.
- ↑ D. K. Grandy (2007). "Trace amine-associated receptor 1—Family archetype or iconoclast?" Pharmacology & Therapeutics 116 (3) 355-390.
- ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Broadley, KJ (March 2010). "The vascular effects of trace amines and amphetamines". Pharmacology & therapeutics 125 (3): 363–75. doi:10.1016/j.pharmthera.2009.11.005. PMID 19948186.
|
---|
| Tyrosine / iodotyrosine | |
---|
| Thyronine / iodothyronine | |
---|
| Thyronamine / iodothyronamine | |
---|
|
|
mt, k, c/g/r/p/y/i, f/h/s/l/o/e, a/u, n, m
|
k, cgrp/y/i, f/h/s/l/o/e, au, n, m, epon
|
m (A16/C10), i (k, c/g/r/p/y/i, f/h/s/o/e, a/u, n, m)
|
|
| |
noco (d)/cong/tumr, sysi/epon
|
proc, drug (A10/H1/H2/H3/H5)
|
|
|
|